Business Context and Reporting Period
This Form 8-K filing by Aclaris Therapeutics, Inc. (Delaware) covers the event date of November 7, 2017. The report addresses a material change in corporate governance and compliance status with the NASDAQ Stock Market, LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a governance event and does not contain financial performance data.
Material Changes
- Board Composition: Richard A. Bierly, an independent member of the Board of Directors and the Audit Committee, died unexpectedly on November 6, 2017.
- Listing Compliance: The vacancy created non-compliance with NASDAQ Listing Rule 5605 regarding the composition of the Audit Committee.
- Regulatory Action: The Company notified NASDAQ on November 7, 2017, and elected to utilize the cure period provided under Listing Rule 5605(c)(4)(B).
Outlook, Risks, and Management Commentary
Management expects to regain compliance with Listing Rule 5605 prior to the expiration of the cure period granted by NASDAQ. The cure period extends until the earlier of the Company's next annual stockholders meeting or November 7, 2018. If the next annual meeting occurs before May 7, 2018, compliance must be evidenced by May 7, 2018.
Investor Verification Checklist
- Confirm the appointment of a new independent director to the Audit Committee to restore full compliance.
- Monitor the date of the next annual stockholders meeting to determine the specific deadline for compliance.
- Review subsequent filings for any updates regarding the Board's composition or further NASDAQ correspondence.